Seres Health, a Cambridge, MA-based clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, closed a $10m Series B financing.
Backers included existing investors Flagship Ventures and Enso Ventures, and new investors Mayo Clinic, Alexandria Venture Investments, and several private investors. The company has also entered into an exclusive research collaboration with the Mayo Clinic.
The company intends to use the funds to advance its pipeline of therapeutics including its lead candidate, SER-109, which is currently in clinical testing for the treatment of recurrent C. difficile.
Launched in 2012 by Dr. Roger J. Pomerantz, President, CEO and Chairman, Seres Health focuses on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome.
Founded by Flagship VentureLabs™, Seres is advancing therapeutics that augments the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.
The Mayo Clinic Center for Individualized Medicine will collaborate with Seres to define diseases for which a microbiome-based intervention may change the course of the illnesses, as well as the discovery and development of key means to treat such conditions.